Literature DB >> 19206206

Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.

Laura Lin1, Robert Czerwinski, Kerry Kelleher, Marshall M Siegel, Paul Wu, Ron Kriz, Ann Aulabaugh, Mark Stahl.   

Abstract

Bruton's tyrosine kinase (Btk) plays a central role in signal transduction pathways regulating survival, activation, proliferation, and differentiation of B-lineage lymphoid cells. A number of cell signaling studies clearly show that Btk is activated by Lyn, a Src family kinase, through phosphorylation on activation loop tyrosine 551 (Y(551)). However, the detailed molecular mechanism regulating Btk activation remains unclear. In particular, we do not fully understand the correlation of kinase activity with Y(551) phosphorylation, and the role of the noncatalytic domains of Btk in the activation process. Insect cell expressed full-length Btk is enzymatically active, but a truncated version of Btk, composed of only the kinase catalytic domain, is largely inactive. Further characterization of both forms of Btk by mass spectrometry showed partial phosphorylation of Y(551) of the full-length enzyme and none of the truncated kinase domain. To determine whether the lack of activity of the kinase domain was due to the absence of Y(551) phosphorylation, we developed an in vitro method to generate Y(551) monophosphorylated Btk kinase domain fragment using the Src family kinase Lyn. Detailed kinetic analyses demonstrated that the in vitro phosphorylated Btk kinase domain has a similar activity as the full-length enzyme while the unphosphorylated kinase domain has a very low k(cat) and is largely inactive. A divalent magnesium metal dependence study established that Btk requires a second magnesium ion for activity. Furthermore, our analysis revealed significant differences in the second metal-binding site among the kinase domain and the full-length enzyme that likely account for the difference in their catalytic profile. Taken together, our study provides important mechanistic insights into Btk kinase activity and phosphorylation-mediated regulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19206206     DOI: 10.1021/bi8019756

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

Review 1.  T-cell signaling regulated by the Tec family kinase, Itk.

Authors:  Amy H Andreotti; Pamela L Schwartzberg; Raji E Joseph; Leslie J Berg
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-02       Impact factor: 10.005

2.  Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Authors:  Julie A Di Paolo; Tao Huang; Mercedesz Balazs; James Barbosa; Kai H Barck; Brandon J Bravo; Richard A D Carano; James Darrow; Douglas R Davies; Laura E DeForge; Lauri Diehl; Ronald Ferrando; Steven L Gallion; Anthony M Giannetti; Peter Gribling; Vincent Hurez; Sarah G Hymowitz; Randall Jones; Jeffrey E Kropf; Wyne P Lee; Patricia M Maciejewski; Scott A Mitchell; Hong Rong; Bart L Staker; J Andrew Whitney; Sherry Yeh; Wendy B Young; Christine Yu; Juan Zhang; Karin Reif; Kevin S Currie
Journal:  Nat Chem Biol       Date:  2010-11-28       Impact factor: 15.040

3.  Identification of an allosteric signaling network within Tec family kinases.

Authors:  Raji E Joseph; Qian Xie; Amy H Andreotti
Journal:  J Mol Biol       Date:  2010-09-06       Impact factor: 5.469

4.  Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.

Authors:  Douglas J Marcotte; Yu-Ting Liu; Robert M Arduini; Catherine A Hession; Konrad Miatkowski; Craig P Wildes; Patrick F Cullen; Victor Hong; Brian T Hopkins; Elisabeth Mertsching; Tracy J Jenkins; Michael J Romanowski; Darren P Baker; Laura F Silvian
Journal:  Protein Sci       Date:  2010-03       Impact factor: 6.725

5.  Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer.

Authors:  Adam C Searleman; Anton B Iliuk; Timothy S Collier; Lewis A Chodosh; W Andy Tao; Ron Bose
Journal:  Electrophoresis       Date:  2014-06-12       Impact factor: 3.535

6.  A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis.

Authors:  Cheryl Eifert; Xianhui Wang; Leila Kokabee; Antonis Kourtidis; Ritu Jain; Michael J Gerdes; Douglas S Conklin
Journal:  Genes Chromosomes Cancer       Date:  2013-08-03       Impact factor: 5.006

7.  Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.

Authors:  Eris Bame; Hao Tang; Jeremy C Burns; Million Arefayene; Klaus Michelsen; Bin Ma; Isaac Marx; Robin Prince; Allie M Roach; Urjana Poreci; Douglas Donaldson; Patrick Cullen; Fergal Casey; Jing Zhu; Thomas M Carlile; Dipen Sangurdekar; Baohong Zhang; Patrick Trapa; Joseph Santoro; Param Muragan; Alex Pellerin; Stephen Rubino; Davide Gianni; Bekim Bajrami; Xiaomei Peng; Alex Coppell; Katherine Riester; Shibeshih Belachew; Devangi Mehta; Mike Palte; Brian T Hopkins; Matthew Scaramozza; Nathalie Franchimont; Michael Mingueneau
Journal:  Clin Transl Immunology       Date:  2021-06-14

Review 8.  Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors.

Authors:  Rula Zain; Mauno Vihinen
Journal:  Front Immunol       Date:  2021-07-19       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.